Ironically, Stan Glantz criticized the study specifically because it examined the effect of electronic cigarettes on quitting among smokers who desired to quit. According to an in the New York Times: "Stanton A. Glantz, a professor of medicine at the University of California, San Francisco, said the study’s limitation was that it tried to measure the effect of e-cigarette use only among smokers who were trying hard to quit, not all smokers."

The biggest problem with Stan's approach is that when you examine e-cigarette users who are not using the product to quit, you are introducing a huge sampling bias. For example, why might someone use e-cigarettes, but not to quit? Most likely, the majority of vapers who are using e-cigarettes for a purpose other than cessation are using e-cigarettes to cut down on the amount they smoke. They are likely to derive benefits from smoking reduction. However, they are almost assuredly not going to quit smoking because they are not trying to quit, nor do they have such a desire.

In contrast to what ANR is stating, the study found no effect of e-cigarettes on lung function, as measured by spirometry. This is in contrast to tobacco smoking, which does have effects on lung function that can be measured using spirometric testing. While previous research indicates that active smoking and even secondhand smoke exposure can affect acute lung function as measured by spirometry, the study demonstrated that electronic cigarette use led to no impairment of lung function detectable via spirometric testing.

1. The financial conflicts of interest involved in these commentaries were not with tobacco companies, but with pharmaceutical companies. Every instance where "tobacco company" appears should be replaced with "pharmaceutical company," and "Big Tobacco" should be replaced with "Big Pharma." The article errantly refers to R.J. Reynolds, Lorillard, Brown & Williamson, Star Scientific, U.S. Tobacco, Liggett, and Santa Fe Natural Tobacco Company. These companies should have been listed as Elan Pharmaceutical, SmithKline Beecham, Glaxo Wellcome, GlaxoSmithKline, Nabi Biopharmaceuticals, Pfizer, Sanofi-Synthelabo, sanofi-aventis, Lederle, Ciba-Geigy, McNeil Consumer Products, and Pharmacia. We apologize for any inconvenience these errors may have caused.

This bill would serve to protect the profits of Big Tobacco. Most troublesome is the fact that it would protect the sale of the most toxic market segment - combustible cigarettes - at the expense of a smoking cessation product that has been shown to be much safer to users.

LAST：weed vaporizer cloutank m8 Newst cloutank cloutank m3 cartomizer |NEXT：aero tank v2 green smoke e vaporizer e cigarette vapor smoke